COVID-19 in August 2026: Where It's Rising, the PQ.16.1.1 Strain, Symptoms, and How to Prepare

COVID-19 in August 2026: Where It's Rising, the PQ.16.1.1 Strain, Symptoms, and How to Prepare

Last verified against the WHO COVID-19 dashboard, WHO Global Respiratory Virus Activity Weekly Update N° 590 (August 12, 2026), the WHO COVID-19 Global Risk Assessment v10 (August 4, 2026), the WHO TAG-VE risk evaluation of PQ.16.1.1 (July 27, 2026), and the CDC Respiratory Illnesses Data Channel (August 14, 2026) on August 14, 2026. This guide is general health information, not medical, legal, financial, or insurance advice — consult qualified professionals and official agencies for decisions about your specific situation.

COVID-19 is climbing again in several parts of the world — but the picture is regional, not a uniform global wave. In WHO's most recent weekly surveillance (week 31, published August 12, 2026), SARS-CoV-2 test positivity remained low and stable globally, but was elevated (above 10%) in Central America and the Caribbean and in Tropical South America, plus single countries in Northern Europe and Western Asia, with rising activity in parts of South-West Europe, Central America, Tropical South America, and Western Africa. In the United States, the CDC reports COVID-19 activity increasing in the West and the South as of August 14, 2026. And in Asia, Thailand reported more new cases to WHO in the past four weeks than every other reporting country combined (28,517 of roughly 35,000 global reported cases between July 5 and August 2). WHO's latest global risk assessment (August 4, 2026) keeps the overall public health risk from COVID-19 at moderate.

The map: reported cases, July 5 – August 2, 2026

!World heatmap of new reported COVID-19 cases by country, July 5 to August 2, 2026, based on WHO dashboard data. Thailand shows the highest reported count, followed by Brazil, Mexico, Colombia, and Greece.

Read this map carefully. It shows cases reported to WHO — and most countries no longer test or report routinely, so grey does not mean zero infections; it usually means no data. Test positivity and wastewater surveillance are now the more reliable signals, and those point to the same hotspots. The top reporters over these four weeks:

Only 45 countries reported any cases at all in this window — a reminder of how sparse official reporting has become. WHO's cumulative totals stand at over 779 million confirmed cases and over 7 million confirmed deaths reported since 2020 (as of June 28, 2026), with seroprevalence studies suggesting the true infection count is orders of magnitude higher.

The surging strain: PQ.16.1.1

The variant behind the most closely watched rise is PQ.16.1.1, designated a Variant Under Monitoring by WHO on July 27, 2026:

• Lineage: a descendant of NB.1.8.1, itself part of the Omicron JN.1 family that has dominated globally since 2024. Its earliest known sample was collected March 25, 2026.
• Growth: it jumped from 2.7% of globally sequenced samples in mid-May to 29.6% by late June 2026 — a substantial growth advantage. So far detections are concentrated in the Western Pacific Region (95.8% of sequences), with Singapore alone accounting for 84.9%.
• What's different: compared with NB.1.8.1 it carries additional spike mutations (D253G, N417T, D420N, I478T) that may confer extra immune escape, though direct laboratory evidence is still limited.
• Severity: surveillance so far shows no increase in clinical severity compared with other circulating variants, and WHO assesses the additional global public health risk as low. WHO states current vaccines are expected to keep protecting against severe disease.
• Other variants WHO is tracking include NB.1.8.1, XFG, LP.8.1 (still dominant in parts of the Americas but declining globally), and BA.3.2. None is associated with more severe illness than earlier Omicron lineages.

Symptoms to watch for

Per the CDC, symptoms of infection with current variants remain the familiar range and can appear 2–14 days after exposure — new variants like PQ.16.1.1 have not produced a distinct symptom profile:

• Fever or chills
• Cough
• Shortness of breath or difficulty breathing
• Sore throat
• Congestion or runny nose
• New loss of taste or smell
• Fatigue
• Muscle or body aches
• Headache
• Nausea, vomiting, or diarrhea

Emergency warning signs — seek immediate care (call your local emergency number): trouble breathing, persistent chest pain or pressure, new confusion, inability to wake or stay awake, or lips/nail beds/skin turning pale, gray, or blue depending on skin tone.

What the treatment research says

Legal disclaimer: The following is a summary of the current treatment research landscape for informational purposes only. It is not a treatment recommendation, medical advice, or an endorsement of any therapy, and it must not be used to make treatment decisions. Individual treatment decisions belong exclusively with a licensed clinician who knows your medical history; several of the drugs discussed are prescription-only and time-sensitive.

The landmark peer-reviewed trials behind today's COVID-19 treatments — every citation below verified against the journal of record.

Remdesivir (Veklury)

• ACTT-1 — Beigel et al., New England Journal of Medicine, 2020 (NEJMoa2007764): the double-blind, placebo-controlled trial (1,062 hospitalized patients) that established remdesivir shortens time to recovery in hospitalized COVID-19 (median 10 vs. 15 days).
• WHO Solidarity — final results, The Lancet, 2022 (S0140-6736(22)00519-000519-0/fulltext)): the largest randomized evaluation (14,304 patients on the remdesivir arm's question) found no significant overall mortality reduction in hospitalized patients, with a suggestion of benefit in those not yet ventilated. A useful counterweight — the two trials together are why guidelines position remdesivir for specific patient groups rather than everyone.
• PINETREE — Gottlieb et al., NEJM, 2022 (NEJMoa2116846): double-blind, placebo-controlled, in outpatients at high risk — a 3-day early course cut hospitalization or death by 87%. Timing is the headline: early treatment is where the antiviral effect is largest.

Nirmatrelvir–ritonavir (Paxlovid)

• EPIC-HR — Hammond et al., NEJM, 2022 (NEJMoa2118542): double-blind, placebo-controlled, 2,246 high-risk unvaccinated outpatients — 89% reduction in hospitalization or death when started within days of symptom onset. This is the basis for the "know your treatment plan in advance" advice below.

Dexamethasone

• RECOVERY — NEJM, 2021 (NEJMoa2021436): the open-label randomized trial (6,425 patients) showing dexamethasone reduces 28-day mortality in hospitalized patients on oxygen or ventilation — and shows no benefit (possible harm) in patients not needing oxygen. Still the backbone of severe-disease treatment.

Lianhua Qingwen (连花清瘟)

The most-studied traditional Chinese medicine for COVID-19, with genuinely peer-reviewed randomized trials — and important caveats:

• Hu, Guan et al., Phytomedicine, 2021 (PMC7229744): multicenter randomized controlled trial, 284 patients — higher 14-day symptom recovery rate (91.5% vs. 82.4%) and faster median symptom recovery (7 vs. 10 days) added to usual care. Key limitations the authors acknowledge: open-label (no placebo, no blinding), and no difference in progression to severe disease or in viral clearance.
• International double-blind RCT, Virology Journal, 2023 (10.1186/s12985-023-02144-6): 815 patients with mild-to-moderate COVID-19, placebo-controlled — shortened median time to sustained symptom improvement (4.0 vs. 6.7 days). Stronger design than the 2020-era trials, but the outcome remains symptom relief, not prevention of severe disease.
• Evidence-quality reviews (e.g., PubMed 35915552) conclude that while trial data support faster symptom recovery, larger high-quality trials are still needed, and no trial has shown Lianhua Qingwen reduces hospitalization or death — the endpoints the antivirals above were tested against.

The honest summary across all of it: for symptom relief in mild illness, Lianhua Qingwen has real randomized-trial support; for preventing severe outcomes in high-risk patients, the strongest evidence belongs to early antivirals (nirmatrelvir–ritonavir, remdesivir), and for the already severely ill, dexamethasone. None of this substitutes for individualized medical advice.

How to prepare for a local surge

Distilled from current WHO and CDC guidance:

1. Keep a small home kit. A few rapid antigen tests (check expiry dates), a working thermometer, fever reducers, and a pulse oximeter if anyone in the household is high-risk. Restock before a surge, not during one.
2. Know your treatment plan in advance. Antivirals work best when started within days of symptom onset. If you or someone you care for is at higher risk, ask a clinician now how you would get tested and prescribed quickly — don't work this out while sick.
3. Test when symptomatic, and stay home while sick. CDC guidance: stay home and away from others until symptoms are improving and you've been fever-free (without medication) for 24 hours, then take added precautions for the following days.
4. Improve air, use masks strategically. Ventilate indoor gatherings, and consider a well-fitting respirator-style mask (N95/FFP2) in crowded indoor spaces, on public transport, and in healthcare settings during a local wave — especially if high-risk.
5. Wash hands and cover coughs. Low-tech, still effective against COVID-19 and the influenza and RSV that co-circulate with it.
6. Review your vaccination status. WHO and the CDC recommend staying current on COVID-19 vaccination, particularly for people 65+, pregnant, immunocompromised, or with chronic conditions. WHO's July 2026 assessment states existing vaccines are expected to continue protecting against severe disease from PQ.16.1.1 and other circulating JN.1-family variants. Discuss timing and suitability with your clinician.
7. Travelers: if you're heading to a current hotspot — Thailand and Southeast Asia, tropical South America, Central America and the Caribbean — pack tests and masks, check your destination's health-ministry advisories, and know how you'd access care abroad.
8. Watch official trackers, not rumors. The WHO COVID-19 dashboard (data.who.int/dashboards/covid19) for global data and your national public-health agency (in the US, the CDC's Respiratory Illnesses Data Channel, updated every Friday) for local activity.

Frequently asked questions

Is COVID-19 surging globally in August 2026?

Not uniformly. WHO's week-31 surveillance (published August 12, 2026) shows global test positivity low and stable, but elevated above 10% in Central America and the Caribbean and Tropical South America, with increases in parts of Europe, Western Africa, and the western and southern United States. Thailand reported 28,517 new cases in four weeks — more than all other reporting countries combined. WHO rates the overall global risk as moderate.

What is the PQ.16.1.1 variant?

PQ.16.1.1 is an Omicron JN.1-family variant descended from NB.1.8.1, first sampled March 25, 2026, and designated a WHO Variant Under Monitoring on July 27, 2026. It grew from 2.7% to 29.6% of global sequences in about seven weeks, driven mostly by Singapore and the Western Pacific. Its extra spike mutations may increase immune escape, but there is no evidence of increased severity, and WHO assesses its additional global risk as low.

Are the symptoms of the new variant different?

No. Health agencies report no distinct symptom profile for PQ.16.1.1 or other current variants. Expect the established range — fever or chills, cough, sore throat, congestion, fatigue, headache, muscle aches, loss of taste or smell, or gastrointestinal symptoms — and treat trouble breathing, chest pressure, new confusion, inability to stay awake, or bluish/gray lips or skin as emergencies.

Do current COVID-19 vaccines still work against the 2026 variants?

According to WHO's July 2026 evaluation, existing vaccines are expected to continue protecting against severe disease from PQ.16.1.1 and the other circulating JN.1-descendant variants. Health agencies note that protection against any infection is lower and fades faster, and both WHO and the CDC direct their strongest vaccination recommendations at people 65+, pregnant, immunocompromised, or chronically ill.

How many COVID-19 cases and deaths have there been in total?

As of June 28, 2026, over 779 million confirmed cases and more than 7 million confirmed deaths had been reported to WHO since 2020. Because routine testing has largely ended, seroprevalence studies indicate the true number of infections is far higher, and only 45 countries reported any cases to WHO in the most recent four-week window.

---

Sources: WHO COVID-19 dashboard · WHO Global Respiratory Virus Activity Weekly Update N° 590 · WHO COVID-19 Global Risk Assessment v10 · WHO TAG-VE Risk Evaluation: PQ.16.1.1 · WHO variant tracking · CDC Respiratory Illnesses Data Channel · CDC COVID-19 Symptoms · WHO advice for the public